New Feature: See every earnings report in one clear view

Arbutus Biopharma Corporation

Contributing Author

Recent Articles by Arbutus Biopharma Corporation

14 hours	Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Jul-16	Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders ABUS GlobeNewswire
May-13	Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Apr-15	Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B ABUS GlobeNewswire
Mar-23	Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Mar-03	Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna ABUS GlobeNewswire
Nov-13	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update ABUS -5.79% GlobeNewswire
Oct-07	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 ABUS GlobeNewswire
Aug-06	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Jun-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus ABUS GlobeNewswire
May-14	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
May-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 ABUS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)